CCR5 and Hepatic fibrosis: CCR5 antagonism may represent a therapeutic strategy for ameliorating hepatic fibrosis in HIV/HCV coinfection, as suggested by studies demonstrating lower rates of progression of liver fibrosis on patients receiving maraviroc, a small molecule inhibitor of CCR5 is used as part of ART [33,34].